<code id='2134C5AAE0'></code><style id='2134C5AAE0'></style>
    • <acronym id='2134C5AAE0'></acronym>
      <center id='2134C5AAE0'><center id='2134C5AAE0'><tfoot id='2134C5AAE0'></tfoot></center><abbr id='2134C5AAE0'><dir id='2134C5AAE0'><tfoot id='2134C5AAE0'></tfoot><noframes id='2134C5AAE0'>

    • <optgroup id='2134C5AAE0'><strike id='2134C5AAE0'><sup id='2134C5AAE0'></sup></strike><code id='2134C5AAE0'></code></optgroup>
        1. <b id='2134C5AAE0'><label id='2134C5AAE0'><select id='2134C5AAE0'><dt id='2134C5AAE0'><span id='2134C5AAE0'></span></dt></select></label></b><u id='2134C5AAE0'></u>
          <i id='2134C5AAE0'><strike id='2134C5AAE0'><tt id='2134C5AAE0'><pre id='2134C5AAE0'></pre></tt></strike></i>

          
          WSS
          Scorecard
          Ryan Pierse/Getty Images

          Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter:

          In December, Vertex Pharmaceuticalsannounced results from a mid-stage clinical trial showing its experimental, non-opioid drug reduced pain in people with diabetes who have chronic pain. This quarter, the company will read out results from Phase 3 studies of the same pain drug, called VX-548, in people with acute pain following surgery.

          advertisement

          The next big test of Alnylam Pharmaceuticals’pipeline of RNA-interference medicines looms with the outcome of a Phase 3 study called HELIOS-B that is investigating vutrisiran as a treatment for ATTR-CM, a progressive disease that leads to heart failure.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          knowledge